NCT05940935

Brief Summary

The relationship of developing metabolic acidosis with antiepleptic drugs in craniotomy operations

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 22, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

June 21, 2023

Completed
9 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

July 11, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 15, 2023

Completed
Last Updated

November 7, 2023

Status Verified

November 1, 2023

Enrollment Period

1 month

First QC Date

June 21, 2023

Last Update Submit

November 2, 2023

Conditions

Keywords

Antiepileptic DrugsMetabolic AcidosisAnesthesia ManagementCraniotomy

Outcome Measures

Primary Outcomes (3)

  • Preoperative Metabolic Acidosis

    The base deficit values in the preoperative, intraoperative and postoperative blood gases taken from the patients and the presence and severity of metabolic acidosis were evaluated. Metabolic acidosis severity was defined by base deficit levels: mild from -3 to -5, moderate from -5 to -10, and severe metabolic acidosis below -10.

    Baseline

  • Intraoperative Metabolic Acidosis

    The base deficit values in the preoperative, intraoperative and postoperative blood gases taken from the patients and the presence and severity of metabolic acidosis were evaluated. Metabolic acidosis severity was defined by base deficit levels: mild from -3 to -5, moderate from -5 to -10, and severe metabolic acidosis below -10.

    during the operation

  • Postoperative Metabolic Acidosis

    The base deficit values in the preoperative, intraoperative and postoperative blood gases taken from the patients and the presence and severity of metabolic acidosis were evaluated. Metabolic acidosis severity was defined by base deficit levels: mild from -3 to -5, moderate from -5 to -10, and severe metabolic acidosis below -10.

    Day 1

Study Arms (4)

Group 1

Patients who have used Zonisamide or Topiramate

Procedure: Arterial Blood Gas Base Deficit

Group 2

Patients who have used Lacosamide

Procedure: Arterial Blood Gas Base Deficit

Group 3

Patients who have used Carbamazepine

Procedure: Arterial Blood Gas Base Deficit

Group 4

Patients who have used levetiracetam

Procedure: Arterial Blood Gas Base Deficit

Interventions

The base deficit values in the preoperative, intraoperative and postoperative blood gases taken from the patients and the presence and severity of metabolic acidosis were evaluated. Metabolic acidosis severity was defined by base deficit levels: mild from -3 to -5, moderate from -5 to -10, and severe metabolic acidosis below -10.

Group 1Group 2Group 3Group 4

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients who underwent craniotomy and intracranial surgery at Trakya University Medical Faculty Hospital and used antiepileptic drugs were included in the study as a retrospective file review. The files of 35 patients who met the study criteria were reviewed retrospectively.

You may qualify if:

  • Patients undergoing intracranial surgery with craniotomy and using antiepileptic drugs
  • ASA I-III
  • Patients undergoing elective surgery

You may not qualify if:

  • Patients with a surgical procedure time of more than 5 hours
  • Patients who received more than 2 units of blood transfusion during the operation
  • Patients taking other drugs that can cause metabolic acidosis
  • Patients with diabetes mellitus, diabetes insipidus, hepatic or renal disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Trakya University

Edirne, Centrum, 22030, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Acidosis

Condition Hierarchy (Ancestors)

Acid-Base ImbalanceMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • SEVTAP HEKİMOĞLU ŞAHİN, Professor

    Trakya University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Department of anesthesiology and reanimation, Principal Investigator, Resident Doctor

Study Record Dates

First Submitted

June 21, 2023

First Posted

July 11, 2023

Study Start

May 22, 2023

Primary Completion

June 30, 2023

Study Completion

August 15, 2023

Last Updated

November 7, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

Locations